Completion of ISO 27001 surveillance audit

Verici Dx

03/11/2025 07:00

RNS Number : 7583F

Verici Dx PLC

03 November 2025

 

 

Verici Dx plc

("Verici Dx" or the "Company")

 

Successful completion of ISO 27001 surveillance audit

 

Verici Dx Plc, (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces that it has successfully completed the annual surveillance audit for its ISO 27001:2022 certification.

 

ISO 27001 is a globally recognised standard specifying data privacy and security requirements for an Information Security Management System ("ISMS"). The annual surveillance audit aims to confirm that the Company is following the highest level of standards enforced by the certification.

 

The Company's successful completion of this audit, along with its continued commitment to protecting sensitive data and information, reinforces its position as a trusted partner in the industry and in patient care. Continued conformity with this standard means that Verici Dx's system meets world-wide best practice with regards to managing risks related to the security of data owned or handled by the Company.

 

Dave Schultenover, VP Quality and Regulatory Affairs at Verici Dx, said: "We take our commitment to compliance at Verici Dx very seriously and pride ourselves on performing with integrity that meets or exceeds industry regulations and standards. We are pleased maintain this strong track record to remain a trusted partner with our stakeholders and within the industry."

 

Verici Dx plc
www.vericidx.com
Sara Barrington, CEO
Via Walbrook PR
Singer Capital Markets (Nominated adviser, Joint Broker)
Tel: +44 (0)20 7496 3000
Phil Davies / Sam Butcher
Oberon Capital (Joint Broker)
Tel: +44 (0)20 3179 0500
Mike Seabrook / Adam Pollock
Walbrook PR (Media & Investor Relations)
Tel: +44 (0)20 7933 8780 or vericidx@walbrookpr.com
Alice Woodings / Paul McManus
Mob: +44 (0)7407 804 654 / +44 (0)7980 541 893


 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 
  END

 

 
NRAEFLFXEBLXFBV